

TABLE 1] Expected Steady-State Peak and Trough Concentrations of Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in Patients With Atrial Fibrillation

Drug	Dose	Peak (ng/mL)	Trough (ng/mL)	References
Dabigatran	150 mg bid	64-443	31-225	120,121
Rivaroxaban	20 mg daily	189-419	6-87	51
Apixaban	5 mg bid	91-321	41-230	94
Edoxaban	60 mg daily	120-250	10-40	12

Samuelson BT et al. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. A Systematic Review. Chest 2017; 151(1):127-138.